Loading
A phase 1/2 trial of NUV-1511 in prostate cancer, pancreatic ductal adenocarcinoma and ovarian cancer, run by Nuvation Bio Inc., active and no longer recruiting.
Safety and Efficacy Study of NUV-1511 in Adult Patients With Advanced Solid Tumors is a phase 1/2 interventional study registered as NCT06334432 by Nuvation Bio Inc., with 466 participants enrolled, started 2024-03-14 and due to reach its primary completion in 2027-03. Interventions recorded: NUV-1511.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Ovarian cancer, Pancreatic ductal adenocarcinoma, Prostate cancer and the tag pipeline.
Shares Ovarian cancer, Pancreatic ductal adenocarcinoma, Prostate cancer and the tag pipeline.
Shares Ovarian cancer, Pancreatic ductal adenocarcinoma, Prostate cancer and the tag pipeline.
Shares Ovarian cancer, Prostate cancer and the tag pipeline.
Shares Ovarian cancer, Pancreatic ductal adenocarcinoma, Prostate cancer and the tag pipeline.
Shares Ovarian cancer, Prostate cancer and the tag pipeline.
Shares Ovarian cancer, Pancreatic ductal adenocarcinoma and the tag pipeline.
Shares Pancreatic ductal adenocarcinoma, Prostate cancer and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/